HSF1 and neoplasm: Notably, normal colonic organoids from patients survived much better using the same combined drug combinations as for PDOs (Figs. 3G and S3C), underlining the tumor selectivity and therapeutic value of dual HSF1-HSP90 pathway inhibition.